Want to see MDT full AI Analyst Report?
MDT Stock Chart & Stats
$83.21
$1.71(2.06%)
At close: 4:00 PM EDT
$83.21
$1.71(2.06%)
Day’s Range― - ―
52-Week Range$73.31 - $106.33
Previous CloseN/A
Volume1.79M
Average Volume (3M)8.03M
Market Cap
$112.06B
Enterprise Value$127.87K
Total Cash (Recent Filing)$9.22B
Total Debt (Recent Filing)$27.96B
Price to Earnings (P/E)23.2
Beta0.30
Next Earnings
Sep 01, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)4.57
Shares Outstanding1,280,045,200
10 Day Avg. Volume6,869,186
30 Day Avg. Volume8,032,971
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)2.16
Price to Sales (P/S)2.94
P/FCF Ratio19.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$95.53Price Target Upside14.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.95
Revenue Forecast (FY)$38.89B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMedtronic’s strong and rising operating cash flow and FCF provide durable funding for R&D, dividends, buybacks and targeted M&A. Reliable cash generation underpins capital allocation optionality and resilience through cyclical elective-procedure swings, supporting long-term strategy execution.
Diversified High-growth Product PortfolioMultiple expanding franchises (CAS, Symplicity, Hugo, Altaviva) reduce single-market dependence and create recurring consumable and upgrade revenue. High adoption rates and installed-base growth create durable follow-on sales and scale benefits across therapy areas over the medium term.
Margin Sustainability And Operational EfficiencyHigh gross margins reflect device mix, pricing power and scale in implantable/high-value products, allowing sustained operating profitability. This margin profile supports continued investment in product development and commercial expansion while cushioning against cost pressures.
Bears Say
High Absolute Debt LoadA sizable absolute debt burden constrains financial flexibility if profitability weakens or rates rise. Even with moderate leverage metrics, interest and refinancing risk can limit aggressive capital deployment, and large debt levels amplify downside in prolonged stress scenarios.
Tariff And Trade UncertaintyOngoing tariff exposure is a structural cost headwind that can erode margins and complicate supply-chain planning. Persistent or expanded trade actions would create recurring COGS pressure, forcing either sustained price increases or margin compression across durable device lines.
Franchise-specific Demand WeaknessSlower demand in Structural Heart/TAVR and pockets like bariatrics create durable headwinds for a material, high‑margin franchise. Prolonged softness requires product/clinical response and could slow installed-base growth, reducing follow-on consumable and upgrade revenue over time.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $73.31 and its highest was $106.33 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $112.06B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Sep 01, 2026 which is in 32 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Jun 03, 2026. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 3.33%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.39.
How many shares outstanding does Medtronic have?
Medtronic has 1,280,045,200 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.55 in its last earnings report, beating expectations of $1.54. Following the earnings report the stock price went up 5.694%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in MDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$95.53 (14.81% Upside)
$95.53 (14.81% Upside)
Blogger Sentiment
Bullish
MDT Sentiment 81%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 267.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $337.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.43%
12-Months-Change
Fundamentals
Return on Equity
3.33%
Trailing 12-Months
Asset Growth
1.47%
Trailing 12-Months
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
MDT Company Deck
MDT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong quarterly and annual revenue growth, EPS outperformance, robust free cash flow, multiple high-growth product area accelerations (CAS, Symplicity, Hugo, Altaviva), and deliberate M&A/venture activity to drive future growth. Notable headwinds include tariffs and trade uncertainty, some product‑mix and Diabetes-related margin pressure, pockets of weakness in Structural Heart (TAVR) and select therapy areas, and near-term investment-driven SG&A/R&D increases. Management provided confident FY '27 guidance while conservatively modeling separation and tariff risks.View all MDT earnings summariesMDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
$95.53
▲(14.81% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
25.53% Mutual Funds
2.72% Other Institutional Investors
47.81% Public Companies and Individual Investors